

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Lipscombe
Date of last notice	4 January 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Richard John Lipscombe <The Luk Trust A/C> Dr Lipscombe is the trustee and a beneficiary of the trust. Bjouxz Pty Ltd <The Loz Superannuation Fund> Dr Lipscombe is beneficiary of the superannuation fund and sole director and shareholder of the trustee.
Date of change	16 March 2018.
No. of securities held prior to change	<i>Direct</i> 9,192,192 fully paid ordinary shares ("Shares") 1,632,423 options exercisable at \$0.20 each on or before 31 March 2018 ("Options") 105 performance rights <i>Indirect</i> 7,061,589 Shares 1,752,898 Options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	(a) Options. (b) Options. (c) Performance rights.
Number acquired	(a) Not applicable. (b) 750,000 Options. (c) Not applicable.
Number disposed	(a) 375,000 Options. (b) 750,000 Options. (c) 30 Performance rights.
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(a) Nil. (b) Nil. (c) Not applicable.
No. of securities held after change	<i>Direct</i> 9,192,192 Shares 882,423 Options 75 performance rights <i>Indirect</i> 7,061,589 Shares 2,127,898 Options
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	(a) Off-market transfer. (b) Off-market transfer from direct holding to superannuation fund. (c) Lapsed in accordance with the terms and conditions.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Terry Sweet
Date of last notice	4 January 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect.
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Sparrow Holdings Pty Ltd <Sweet Super Fund> Mr Sweet is a beneficiary of the superannuation fund and a director and shareholder of the trustee.
Date of change	16 March 2018
No. of securities held prior to change	1,098,000 fully paid ordinary shares ("Shares") 2,758,875 options exercisable at \$0.20 each on or before 31 March 2018 ("Options").
Class	Options.
Number acquired	Nil.
Number disposed	375,000 Options.
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	1,098,000 Shares. 2,383,875 Options.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market transfer.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Dunlop
Date of last notice	4 January 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Randolph Resources Pty Ltd Dr Dunlop is a director and shareholder of the company.
Date of change	23 March 2018
No. of securities held prior to change	<i>Direct</i> 3,855,188 fully paid ordinary shares ("Shares") 28 performance rights <i>Indirect</i> 1,574,000 Shares 375,000 options exercisable at \$0.20 each on or before 31 March 2018 ("Options")
Class	(a) Shares. (b) Performance rights
Number acquired	(a) 375,000 Shares. (b) Not applicable.
Number disposed	(a) 375,000 Options. (b) 12 performance rights.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(a) \$75,000. (b) Not applicable.
No. of securities held after change	<i>Direct</i> 3,855,188 Shares. 16 performance rights. <i>Indirect</i> 1,949,000 Shares.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	(a) Exercise of Options. (b) Lapsed in accordance with the terms and conditions.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
--	-----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Roger Moore
Date of last notice	13 September 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect.
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Moore and Sotomi Investments Pty Ltd <Roger Moore Family A/C> Mr Moore is a director and shareholder of the trustee and a beneficiary of the trust.
Date of change	a. 16 March 2018. b. 23 March 2018.
No. of securities held prior to change	<i>Direct</i> Nil. <i>Indirect</i> 252,000 fully paid ordinary shares ("Shares")
Class	a. Options exercisable at \$0.20 each option on or before 31 March 2018 ("Options"). b. Shares.
Number acquired	a. 375,000 Options. b. 375,000 Shares.
Number disposed	a. 375,000 Options. b. Not applicable.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	a. Nil. b. \$75,000.
--	-------------------------

No. of securities held after change	<i>Direct</i> Nil. <i>Indirect</i> 627,000 Shares.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	a. Off-market transfer. b. Exercise of Options.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	

+ See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this provided?	
---	--

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Edward House
Date of last notice	23 November 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Baljuna Capital Pty Ltd Mr House is a director and shareholder of the company.
Date of change	a. 16 March 2018 b. 23 March 2018.
No. of securities held prior to change	<i>Direct</i> Nil. <i>Indirect</i> Nil.
Class	a. Options exercisable at \$0.20 each option on or before 31 March 2018 ("Options"). b. Fully paid ordinary shares ("Shares").
Number acquired	a. 375,000 Options. b. 375,000 Shares.
Number disposed	a. 375,000 Options. b. Not applicable.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	a. Nil. b. \$75,000.
No. of securities held after change	<i>Direct</i> Nil. <i>Indirect</i> 375,000 Shares.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	a. Off-market transfer. b. Exercise of Options.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	

+ See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this provided?	
---	--